The Physicians at Retina Vitreous Consultants are involved in a number of research projects to help define new treatments for many different retinal conditions. Several of these studies are described below. You may be offered the opportunity to participate in one of these studies but you are never required to participate. If you choose not to participate, or if you do not qualify for a research study, we will still provide you with the best possible care in our clinic.

Current Reasearch Studies


Santen Sakura
This section is under construction.  Please check back later for updates

 

Completed Research Studies

 

Alcon See
The standard of care treatment for wet macular degeneration is anti-VEGF therapy (Lucentis or Avastin). ESBA1008 is a small fragment of an anti-VEGF molecule. This study compares one dose of the investigational drug, ESBA1008, with one dose of Lucentis. The goal of this Phase I study is to determine the safety, tolerability and effects of ESBA1008.
For more information regarding this trial see:

http://www.clinicaltrials.gov/ct2/show/NCT01304693

Regeneron VISTA
Diabetic macular edema is the most common cause of vision loss in diabetics. Current treatment for diabetic macular edema is either laser or anti-VEGF injections (Lucentis/Avastin). In this Phase III trial, VEGF Trap, an anti-VEGF medication already approved for the treatment of wet-macular degeneration, is being compared to laser for the treatment of diabetic macular edema.
For more information regarding this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT01363440

Fovea
Diabetic macular edema is the most common cause of vision loss in diabetics. Current treatment from diabetic macular edema is laser or anti-VEGF injections. This Phase II trial compares an experimental eye drop to placebo eye drops in patients with diabetic macular edema.
For more information regarding this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT01319487

DRCR.net Protocol R
Some patients have diabetic macular edema that has not yet involved the center of the macula. These patients are not good candidates for anti-VEGF therapy. This Phase II trial evaluates non-steroidal anti-inflammatory eye drops in the treatment of patients with non-central diabetic macular edema.
For more information regarding this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT01331005

Genentech SHORE
Lucentis is an anti-VEGF antibody approved by the FDA for use in patients with macular edema secondary to retinal vein occlusion. This study looks at the effectiveness of different Lucentis dosing regimens in patients with retinal vein occlusion and macular edema.
For more information regarding this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT01277302

Brimonidine for Geographic Atrophy from Age related Macular Degeneration
Geographic atrophy (GA) is the atrophic or dry form of Age Related Macular Degeneration. GA is a major cause of both moderate and severe central visual loss. There is currently no established treatment to prevent GA or to slow its progression. Brimonidine is a medication having some neuroprotective action and which may therefore improve the function of surviving retinal cells. The goal of this study is to evaluate the safety and efficacy of the Brimo PS DDS Applicator System (200 μg and 400 μg brimonidine tartrate) in patients with geographic atrophy (GA) from age-related macular Degeneration.
For more information on this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT00658619

AREDS 2
AREDS (Age Related Eye Disease Study) was completed in 2001 and demonstrated that certain high dose vitamins can reduce the progression of dry to wet macular degeneration. AREDS 2 is a follow-up study designed to evaluate additional supplements (lutein, zeaxanthin and omega-3 fatty acids) to see if they have additional benefit.
For more information on this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT00345176

Genentech HARBOR
Lucentis is an FDA approved drug for the treatment of wet macular degeneration. However, Lucentis injections are generally required on a monthly basis. This study compares the regular dose of Lucentis with a higher dose of the same medication. Hopefully, the higher dose will be more effective or possibly allow for less frequent dosing.
For more information on this trial see:
http://clinicaltrials.gov/ct2/show/NCT00891735

CATT
The Comparison of AMD Treatment Trials (CATT) is a research trial designed to determine which of two widely used treatments for the wet form of AMD may be preferable.
In the study patients will be assigned to receive either a Lucentis or Avastin injection into the eye, in either a fixed dosage schedule, or in a variable dosage schedule. One-year results demonstrated that Lucentis and Avastin were equivalent in their effect on vision. The study will continue to follow patients for two years.
For more information on this trial see:
http://clinicaltrials.gov/ct2/show/NCT00593450

Focus, Marina, Pier and Horizon
These studies demonstrated the benefit of anti-VEGF injections (Lucentis) in the treatment of wet macular degeneration. As a result of these studies, Lucentis was approved for use by the FDA. This new treatment has dramatically changed the way we treat wet macular degeneration. Far fewer patients lose vision once this treatment is begun and many will have some improvement.

Sailor
This was a study comparing different doses of Lucentis in patients with wet macular degeneration. This study further defined the benefits and the safety of Lucentis injections in wet macular degeneration.
For more information on this trial see:
http://www.clinicaltrials.gov/ct2/show/NCT00251459

CRUISE and BRAVO
These studies demonstrated the benefit of ranibizumab (Lucentis) for the treatment of central retinal vein occlusion (CRUISE study) and branch retinal vein occlusion (BRAVO study). For more information on these studies see:
http://clinicaltrials.gov/ct2/show/NCT00485836
http://clinicaltrials.gov/ct2/show/NCT00486018

Standard Care vs. Corticosteroid for Retinal Vein Occlusion Study
The SCORE Study was a multi-center, randomized Phase III trial designed to assess the efficacy and safety of standard care versus steroid (triamcinolone acetonide) injection(s) for the treatment of macular edema associated with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).
For more information on this study see:
http://clinicaltrials.gov/ct2/show/NCT00105027

Submacular Surgery Trials (SST)
The Submacular Surgery Trials was a study to evaluate the role of surgery in the treatment of wet macular degeneration and younger patients with ocular histoplasmosis. RVC was one of 30 centers in study is sponsored by the National Eye Institute a branch of the National Institute of Health.
For more information on this study see:
http://clinicaltrials.gov/ct2/show/NCT00000150

Collaborative Ocular Melanoma Study (COMS)
The Collaborative Ocular Melanoma Study (COMS) was a study that helped define the treatment of choroidal melanoma, the most common primary eye cancer affecting adults. Retina Vitreous Consultants was one of 40 centers throughout the country for this study supported by the National Eye Institute.
For more information on this study see:
http://clinicaltrials.gov/ct2/show/NCT00000124

Endophthalmitis Vitrectomy Study (EVS)
The Endophthalmitis Vitrectomy Study was a study that helped define the optimal treatment for patients that develop infections following cataract surgery. This study has changed the way many retina specialists treat such infections. This was a large multi-centered study sponsored by the National Eye Institute. Dr. Doft of Retina Vitreous Consultants was the chairman of this important study.
For more information on this study see:
http://clinicaltrials.gov/ct2/show/NCT00000130